Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


False Lancet study

This article was originally published in The Tan Sheet

Executive Summary

The Lancet has "received confirmation" that a study published by the journal in October on NSAIDs and reduction of oral cancer contains fabricated data, the publication announces Feb. 4. The false data was provided by lead author John Sudbo, MD/PhD, Norwegian Radium Hospital. The journal's editors released an "expression of concern" about the fabricated data Jan. 17 when they were first alerted to the problem (1"The Tan Sheet" Jan. 23, 2005, In Brief)...

You may also be interested in...

Lancet study a sham?

Editors of The Lancet issued an "expression of concern" Jan. 17 about a study published in the journal in October which appeared to be based on "complete fabrication" by the study's lead author. John Sudbo, MD, PhD, Norwegian Radium Hospital, et al., found in a study that long-term use of NSAIDs was linked to reduced incidence of oral cancer but increased risk of death from cardiovascular disease. The hospital alerted Lancet editors to the problem Jan. 13, and the publication states that "the journal has not yet received written confirmation...that fabrication actually took place." The hospital has appointed an investigation committee to look into the matter. Sudbo's findings were first presented at the American Association for Cancer Research annual meeting in April (1"The Tan Sheet" April 25, 2005, p. 10)...

No Eudamed, No Problem! Latest Guidance Explains Alternatives While Database Is Built

Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.

David Now Goliath? Made In China PD-1s Sought After By Multinationals

From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts